Monthly information related to total number of voting rights and shares composing the share capital – March 31 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
ERYTECH to Present Novel Vesiculation Approach at the 24 th M eeting of the European Red Cell Society Oral presentation detailing the feasibility of producing cargo-loaded extracellular vesicles derived from red blood cell s that have been loaded using the ERYCAPS® process, ERYCEV TM Cambridge, MA
ERYTECH to Participate in the Upcoming April Investor Conferences Cambridge, MA (U.S.) and Lyon (France), March 28 , 202 2 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 20 2 1 Conference call and webcast on Tuesday, March 14, 2022 at 8:30am EDT / 1:30pm CET Progress towards seeking approval of GRASPA® for the treatment of ALL patients with hypersensitivity to pegylated
Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website :
ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases Cambridge, MA (U.S.) and Lyon (France), February 8 , 202 2 – ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic
Monthly information related to total number of voting rights and shares composing the share capital – January 3 1 , 202 2 . Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
ERYTECH Announces P resentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI Interim results from the Phase 1 rESPECT trial of eryaspase plus mFOLFIRINOX as first-line treatment for advanced pancreatic cancer patients , presented in a poster presentation, confirm
Monthly information related to total number of voting rights and shares composing the share capital – December 3 1 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
ERYTECH to Participate in the Upcoming January Virtual Investor Conferences Cambridge, MA (U.S.) and Lyon (France), January 3 , 202 2 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances
